Left ventricular hypertrophy (LVH) has been shown to be an independent risk factor for adverse cardiac and cerebrovascular events. Despite this well-known association, the lack of a standardized approach for both the quantification of LVH and the monitoring of LVH regression has limited its use as a primary risk factor that can be clinically targeted. In this State of the Art Paper, we will provide a current appraisal of LVH with a focus on presenting the current methods to accurately detect LVH and management strategies to develop a therapeutic target for clinicians.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!